FAM221B Inhibitors

The compounds such as LY294002 and Wortmannin are known to inhibit PI3K, thereby potentially affecting the Akt signaling pathway, which is a key regulator of numerous cellular processes including protein interactions that could involve FAM221B. MEK inhibitors like PD98059 and U0126 can suppress the MAPK/ERK pathway, potentially altering functions of proteins associated with this pathway including FAM221B. Similarly, the JNK inhibitor SP600125 and the p38 MAPK inhibitor SB203580 can modulate their respective MAPK pathways, affecting associated protein functions.

Rapamycin and Triciribine are mTOR and Akt inhibitors, respectively, that intervene in the mTOR/Akt signaling axis, which is a crucial regulatory pathway for cell growth and metabolism, and modulation of this pathway can influence proteins connected to it. Y-27632, a Rho kinase inhibitor, and NSC 23766, a Rac1 inhibitor, target cytoskeletal dynamics and related signaling pathways, which can have implications for proteins involved in these processes. ML141, which inhibits Cdc42, and ZINC00897085, which targets GEFs, can impact actin polymerization and GEF-mediated signaling, respectively.